+10.9%
CMG vs MRNA
+945.0%
-934.1%
-32.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.8% | +13.1% | -7.3% | +5.5% |
| 7D | +22.5% | +20.6% | +1.9% | +21.9% |
| 30D | +14.1% | +27.1% | -13.0% | +13.3% |
| 3M | +4.1% | +353.4% | -349.3% | -3.6% |
| 6M | +10.1% | +446.3% | -436.2% | 0.0% |
| YTD | -4.9% | +776.2% | -781.0% | -15.9% |
| 1Y | +10.9% | +987.9% | -977.0% | -4.1% |
| All | +10.9% | +945.0% | -934.1% | -4.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling